Estimating the efficacy of preexposure prophylaxis for HIV prevention among participants with a threshold level of drug concentration

American Journal of Epidemiology

Volumn 177, Issue 3, 2013, Pages 256-263

  Dai, James Y ^a,b   Gilbert, Peter B ^a,b   Hughes, James P ^a,b   Brown, Elizabeth R ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

causal inference; compliance; exclusion restriction; potential outcome; principal stratification; two phase sampling

Indexed keywords

BIOLOGICAL MARKER; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLACEBO; TENOFOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CONCENTRATION (COMPOSITION); CORRELATION; DISEASE CONTROL; DRUG; HUMAN IMMUNODEFICIENCY VIRUS; SAMPLING; SENSITIVITY ANALYSIS;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BLOOD SAMPLING; CAUSAL ATTRIBUTION; CLINICAL TRIAL; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG EFFICACY; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFECTION PREVENTION; INFECTION RISK; PATIENT COMPLIANCE; PROPHYLAXIS; SENSITIVITY ANALYSIS; SEROCONVERSION; SOUTH AFRICA;

ANTI-RETROVIRAL AGENTS; HIV INFECTIONS; HUMANS; MEDICATION ADHERENCE; MODELS, THEORETICAL; PREVENTIVE HEALTH SERVICES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; SOUTH AFRICA;

SOUTH AFRICA;

EID: 84874491627     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kws324     Document Type: Article

References (30)

1. The iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587-2599.
2. Karim QA, Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010; 329(5996):1168-1174.
3. Kelesidis T, Landovitz RJ. Preexposure prophylaxis for HIV prevention. Curr HIV/AIDS Rep. 2011;8(2): 94-103.
4. Skoler-Karpoff S, Ramjee G, Ahmed K, et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9654):1977-1987.
5. Karim SS, Kashuba AD, Werner L, et al. Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. Lancet. 2011; 378(9787):279-281.
6. Splawa-Neyman J. On the application of probability theory to agricultural experiments. Essay on principles. Section 9. Stat Sci. 1990;5(4):465-472.
7. Rubin DB. Estimating causal effects of treatments in randomized and nonrandomized studies. J Educ Psychol. 1974;66(5):688-701.
8. Rubin DB. Bayesian inference for causal effects: the role of randomization. Ann Stat. 1978;6(1):34-58.
9. Holland PW. Statistics and causal inference. J Am Stat Assoc. 1986;81(396):945-960.
10. Sommer A, Zeger SL. On estimating efficacy from clinical trials. Stat Med. 1991;10(1):45-52.
11. Follmann DA. On the effect of treatment among would-be treatment compliers: an analysis of the Multiple Risk Factor Intervention Trial. J Am Stat Assoc. 2000;95(452): 1101-1109.
12. Rubin DR. More powerful randomization-based p-values in double-blind trials with non-compliance. Stat Med. 1998; 17(3):371-385.
13. Imbens GW, Rubin DB. Bayesian inference for causal effects in randomized experiments with noncompliance. Ann Stat. 1997;25(1):305-327.
14. Angrist JD, Imbens GW, Rubin DB. Identification of causal effects using instrumental variables. J Am Stat Assoc. 1996;91(434):444-455. (Pubitemid 126412813)
15. Frangakis CE, Rubin DB. Addressing complications of intention-to-treat analysis in the combined presence of all-or-none treatment-noncompliance and subsequent missing outcomes. Biometrika. 1999;86(2):365-379. (Pubitemid 129767156)
16. Robins J, Rotnitzky A. Estimation of treatment effects in randomised trials with non-compliance and a dichotomous outcome using structural mean models. Biometrika. 2004; 91(4):763-783. (Pubitemid 41388918)
17. Rosenbaum PR. The consequences of adjustment for a concomitant variable that has been affected by treatment. J R Stat Soc Ser A. 1984;147(5):656-666.
18. Frangakis CE, Rubin DB. Principal stratification in causal inference. Biometrics. 2002;58(1):21-29. (Pubitemid 34194484)
19. Follmann D. Augmented designs to assess immune response in vaccine trials. Biometrics. 2006;62(4):1161-1169.
20. Gilbert PB, Hudgens MG. Evaluating candidate principal surrogate endpoints. Biometrics. 2008;64(4):1146-1154.
21. Gilbert PB, Bosch R, Hudgens MG. Sensitivity analysis for the assessment of vaccine effects on viral load in HIV vaccine trials. Biometrics. 2003;59(3):531-541. (Pubitemid 37093392)
22. Shepherd BE, Gilbert PB, Dupont TC. Sensitivity analyses comparing time-to-event outcomes only existing in a subset selected post-randomization and relaxing monotonicity. Biometrics. 2011;67(3):1100-1110.
23. Rubin DB. Inference and missing data. Biometrika. 1976;63:581-592.
24. White JE. A two-stage design for the study of the relationship between a rare exposure and a rare disease. Am J Epidemiol. 1982;115(1):119-128. (Pubitemid 12205727)
25. Scott AJ, Wild CJ. Fitting logistic regression models in stratified case-control studies. Biometrics. 1991;47(2):497-510.
26. Ibrahim JG. Incomplete data in generalized linear models. J Am Stat Assoc. 1990;85(411):765-769.
27. Louis TA. Finding the observed information when using the EM algorithm. J R Stat Soc Series B. 1982;44(2):226-233.
28. Robins JM, Greenland S. Comment on Angrist, Imbens and Rubin: estimation of the global average treatment effects using instrumental variables. J Am Stat Assoc. 1996;91(434): 456-458.
29. Robins JM. Correction for non-compliance in equivalence trials. Stat Med. 1997;17(3):269-302. (Pubitemid 28051099)
30. Green MS, Symons MJ. A comparison of the logistic risk function and the proportional hazards model in prospective epidemiologic studies. J Chronic Dis. 1983; 36(10):715-724.